These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast. Pickar JH; Komm BS Post Reprod Health; 2015 Sep; 21(3):112-21. PubMed ID: 26289836 [TBL] [Abstract][Full Text] [Related]
3. Chemoprevention of breast cancer: implications for postmenopausal women. Fabian CJ; Kimler BF Drugs Aging; 2002; 19(1):43-78. PubMed ID: 11929326 [TBL] [Abstract][Full Text] [Related]
5. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. Jordan VC; Gapstur S; Morrow M J Natl Cancer Inst; 2001 Oct; 93(19):1449-57. PubMed ID: 11584060 [TBL] [Abstract][Full Text] [Related]
6. Effect of hormone replacement therapies and selective estrogen receptor modulators in postmenopausal women with uterine leiomyomas: a literature review. Ang WC; Farrell E; Vollenhoven B Climacteric; 2001 Dec; 4(4):284-92. PubMed ID: 11770184 [TBL] [Abstract][Full Text] [Related]
7. Novel agents to modulate oestrogen action. Dardes RC; Jordan VC Br Med Bull; 2000; 56(3):773-86. PubMed ID: 11255561 [TBL] [Abstract][Full Text] [Related]
8. Selective estrogen receptor modulators and phytoestrogens: new therapies for the postmenopausal women. Fitzpatrick LA Mayo Clin Proc; 1999 Jun; 74(6):601-7. PubMed ID: 10377937 [TBL] [Abstract][Full Text] [Related]
9. The role of selective estrogen receptor modulators (SERMs) in postmenopausal health. Draper MW Ann N Y Acad Sci; 2003 Nov; 997():373-7. PubMed ID: 14644844 [TBL] [Abstract][Full Text] [Related]
11. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy. McKeage K; Curran MP; Plosker GL Drugs; 2004; 64(6):633-48. PubMed ID: 15018596 [TBL] [Abstract][Full Text] [Related]
12. [What can we expect of raloxifene in the treatment of postmenopausal osteoporosis--views of a gynecologist]. Chmel R; Rob L; Strnad P Ceska Gynekol; 2002 Jul; 67(4):187-91. PubMed ID: 12373918 [TBL] [Abstract][Full Text] [Related]
13. Raloxifene: a new choice for treating and preventing osteoporosis. Licata AA; Ciaccia AV; Wong M; Draper MW Cleve Clin J Med; 2000 Apr; 67(4):273-80. PubMed ID: 10780099 [TBL] [Abstract][Full Text] [Related]
14. Raloxifene: A selective estrogen receptor modulator (SERM) with multiple target system effects. Muchmore DB Oncologist; 2000; 5(5):388-92. PubMed ID: 11040275 [TBL] [Abstract][Full Text] [Related]
15. The effects of estrogen and selective estrogen receptor modulators on cardiovascular risk factors. Walsh BW Ann N Y Acad Sci; 2001 Dec; 949():163-7. PubMed ID: 11795349 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of raloxifene and its clinical application. Hochner-Celnikier D Eur J Obstet Gynecol Reprod Biol; 1999 Jul; 85(1):23-9. PubMed ID: 10428318 [TBL] [Abstract][Full Text] [Related]
17. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer. Ganz PA; Land SR Menopause; 2008; 15(4 Suppl):797-803. PubMed ID: 18596601 [TBL] [Abstract][Full Text] [Related]